Please use this identifier to cite or link to this item:
Title: New dinuclear palladium(II) complexes with benzodiazines as bridging ligands: interactions with CT-DNA and BSA, and cytotoxic activity
Authors: Franich A.
Zivkovic, Marija
Ćoćić, Dušan
Petrović, Biljana
Milovanovic, Marija
Arsenijevic A.
Milovanovic, Jelena
Arsenijevic D.
Stojanovic B.
Djuran, Miloš
Rajković, Snežana
Issue Date: 2019
Abstract: © 2019, Society for Biological Inorganic Chemistry (SBIC). Abstract: Three new dinuclear Pd(II) complexes with general formula [{Pd(en)Cl}2(μ-L)](NO3)2 [L is bridging ligand quinoxaline (Pd1), quinazoline (Pd2) and phthalazine (Pd3)] were synthesized and characterized by elemental microanalyses, UV–Vis, IR and NMR (1H and 13C) spectroscopy. The interaction of dinuclear Pd1–Pd3 complexes with calf thymus DNA (CT-DNA) has been monitored by viscosity measurements, UV–Vis and fluorescence emission spectroscopy in aqueous phosphate buffer solution (PBS) at pH 7.40 and 37 °C. In addition, these experimental conditions have been applied to investigate the binding affinities of Pd1–Pd3 complexes to the bovine serum albumin (BSA) by fluorescence emission spectroscopy. In vitro antiproliferative and apoptotic activities of the dinuclear Pd(II) complexes have been tested on colorectal and lung cancer cell lines. All tested Pd(II) complexes had lower cytotoxic effect than cisplatin against colorectal cancer cells, but also had similar or even higher cytotoxicity than cisplatin against lung cancer cells. All complexes induced apoptosis of colorectal and lung cancer cells, while the highest antiproliferative effect exerted Pd2 complex. Graphic abstract: [Figure not available: see fulltext.]
Type: article
DOI: 10.1007/s00775-019-01695-w
ISSN: 0949-8257
SCOPUS: 2-s2.0-85070211794
Appears in Collections:Faculty of Medical Sciences, Kragujevac
Faculty of Science, Kragujevac

Page views(s)




Files in This Item:
File Description SizeFormat 
  Restricted Access
29.86 kBAdobe PDFThumbnail

Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.